Abstract
Acknowledgements
Notes
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
Figure 1
Study design; treatment A, atorvastatin 40 mg once daily for seven days; treatment B, ezetimibe 10 mg once daily for seven days; treatment C, co-administration of atorvastatin 40 mg and ezetimibe 10 mg once daily for seven days.
![tcp-25-202-g001](/upload/SynapseXML/1179tcp/thumb/tcp-25-202-g001.jpg)
Figure 2
Plasma concentration-time profiles of atorvastatin with or without ezetimibe at steady state plotted using (a) linear and (b) log-linear scales, and of 2-hydroxyatorvastatin (c) linear and (d) log-linear scales.
![tcp-25-202-g002](/upload/SynapseXML/1179tcp/thumb/tcp-25-202-g002.jpg)
Figure 3
Plasma concentration-time profiles of total ezetimibe with or without atorvastatin at steady state plotted using (a) linear and (b) log-linear scales, and of free ezetimibe (c) linear and (d) log-linear scales.
![tcp-25-202-g003](/upload/SynapseXML/1179tcp/thumb/tcp-25-202-g003.jpg)
Table 1
Demographic characteristics of each treatment sequence
![tcp-25-202-i001](/upload/SynapseXML/1179tcp/thumb/tcp-25-202-i001.jpg)
Table 2
Pharmacokinetic parameters of atorvastatin and 2-hydroxyatorvastatin
![tcp-25-202-i002](/upload/SynapseXML/1179tcp/thumb/tcp-25-202-i002.jpg)
*Median (min–max). GMR, geometric mean ratio; CI, confidence interval. Treatment A, atorvastatin 40 mg once daily for seven days; treatment C, co-administration of atorvastatin 40 mg and ezetimibe 10 mg once daily for seven days. Tmax, time to reach maximum plasma concentration; Cmax,ss, maximum plasma concentration at steady state; AUCτ,ss, area under the plasma concentration-time curve within a dosing interval at steady state; AUCinf,ss, area under the plasma concentration-time curve from dosing time extrapolated to infinity at steady state; t1/2, elimination half-life; CLss/F, apparent clearance; Vdss/F, apparent volume of distribution.
Table 3
Pharmacokinetic parameters of total ezetimibe and free ezetimibe
![tcp-25-202-i003](/upload/SynapseXML/1179tcp/thumb/tcp-25-202-i003.jpg)
*Median (min–max). GMR, geometric mean ratio; CI, confidence interval. Treatment B, ezetimibe 10 mg once daily for seven days; treatment C, co-administration of atorvastatin 40 mg and ezetimibe 10 mg once daily for seven days; Tmax, time to reach maximum plasma concentration; Cmax,ss, maximum plasma concentration at steady state; AUCτ,ss, area under the plasma concentration-time curve within a dosing interval at steady state; AUCinf,ss, area under the plasma concentration-time curve from dosing time extrapolated to infinity at steady state; t1/2, elimination half-life; CLss/F, apparent clearance; Vdss/F, apparent volume of distribution.